{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T16:38:09Z","timestamp":1765039089947},"reference-count":128,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.blre.2009.11.003","type":"journal-article","created":{"date-parts":[[2010,1,7]],"date-time":"2010-01-07T09:16:40Z","timestamp":1262855800000},"page":"51-61","source":"Crossref","is-referenced-by-count":43,"title":["Current therapeutic approaches to fungal infections in immunocompromised hematological patients"],"prefix":"10.1016","volume":"24","author":[{"given":"Livio","family":"Pagano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morena","family":"Caira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina Giovanna","family":"Valentini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brunella","family":"Posteraro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luana","family":"Fianchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2009.11.003_bib1","first-page":"1068","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study","volume":"91","author":"Pagano","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2009.11.003_bib2","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1086\/592255","article-title":"Factors associated with overall and attributable mortality in invasive aspergillosis","volume":"47","author":"Nivoix","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib3","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1086\/522189","article-title":"Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study","volume":"45","author":"Pagano","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib4","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1046\/j.1365-2141.2002.03414.x","article-title":"Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study involving 720 patients with haematological malignancy","volume":"117","author":"Kami","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2009.11.003_bib5","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1086\/339202","article-title":"Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients","volume":"34","author":"Marr","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib6","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1086\/322606","article-title":"Trends in mortality due to invasive mycotic diseases in the United States, 1980\u20131997","volume":"33","author":"McNeil","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib7","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1600-0609.2004.00273.x","article-title":"Invasive fungal infections in autologous stem cell transplant recipients: a nation-wide study of 1188 transplanted patients","volume":"73","author":"Jantunen","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2009.11.003_bib8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1600-0609.1999.tb01120.x","article-title":"Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes","volume":"63","author":"Pagano","year":"1999","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2009.11.003_bib9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/315193","article-title":"Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole","volume":"181","author":"Marr","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib10","first-page":"207","article-title":"Mucormycosis in hematologic patients","volume":"89","author":"Pagano","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2009.11.003_bib11","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1086\/313803","article-title":"Zygomycosis in the 1990s in a tertiary-care cancer center","volume":"30","author":"Kontoyiannis","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib12","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1046\/j.1365-2141.2000.02312.x","article-title":"The epidemiology of fusariosis in patients with haematological diseases","volume":"111","author":"Girmenia","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2009.11.003_bib13","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1128\/JCM.43.4.1818-1828.2005","article-title":"Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature","volume":"43","author":"Girmenia","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.blre.2009.11.003_bib14","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3324\/haematol.11740","article-title":"Scedosporiosis in patients with acute leukemia: a retrospective multicenter report","volume":"93","author":"Caira","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2009.11.003_bib15","first-page":"974","article-title":"Prevention of fungal infections in the immunocompromised host","volume":"4","author":"Mahfouz","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.blre.2009.11.003_bib16","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.bbmt.2008.04.006","article-title":"Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation","volume":"14","author":"Hamadani","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2009.11.003_bib17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/504811","article-title":"Infectious complications associated with alemtuzumab use for lymphoproliferative disorders","volume":"43","author":"Martin","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib18","doi-asserted-by":"crossref","first-page":"345","DOI":"10.7326\/0003-4819-100-3-345","article-title":"Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia","volume":"100","author":"Gerson","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2009.11.003_bib19","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1099\/13500872-140-9-2475","article-title":"Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis","volume":"140","author":"Ng","year":"1994","journal-title":"Microbiology"},{"key":"10.1016\/j.blre.2009.11.003_bib20","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.diagmicrobio.2007.01.005","article-title":"Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals","volume":"58","author":"Bassetti","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib21","first-page":"192","article-title":"Symptoms and diagnosis of nosocomial fungal infections\u2013state-of-the-art","volume":"7","author":"Donnelly","year":"2002","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.blre.2009.11.003_bib22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1128\/CMR.18.1.44-69.2005","article-title":"Aspergillus infections in transplant recipients","volume":"18","author":"Singh","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.blre.2009.11.003_bib23","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/QCO.0b013e32832e074d","article-title":"Prevention and treatment of invasive fungal diseases in neutropenic patients","volume":"22","author":"Almyroudis","year":"2009","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib24","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1086\/429921","article-title":"Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay","volume":"40","author":"Marr","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib25","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1086\/383148","article-title":"Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies","volume":"38","author":"Adam","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib26","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1086\/503427","article-title":"Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis","volume":"42","author":"Pfeiffer","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib27","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1086\/421944","article-title":"Beta-d-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome","volume":"39","author":"Odabasi","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1128\/JCM.00506-08","article-title":"Utility of galactomannan enzyme immunoassay and (1\u21923) beta-d-glucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients","volume":"47","author":"Hachem","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.blre.2009.11.003_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1574-6968.2009.01575.x","article-title":"An update on the molecular diagnosis of invasive fungal disease","volume":"296","author":"White","year":"2009","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.blre.2009.11.003_bib30","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib31","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1128\/JCM.01086-08","article-title":"Detection of circulating Aspergillus fumigatus DNA by real-time PCR assay of large serum volumes improves early diagnosis of invasive aspergillosis in high-risk adult patients under hematologic surveillance","volume":"46","author":"Suarez","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.blre.2009.11.003_bib32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1473-3099(09)70019-2","article-title":"Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis","volume":"9","author":"Mengoli","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib33","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1128\/JCM.43.5.2181-2187.2005","article-title":"Comparison of non-culture-based methods for detection of systemic fungal infections, with an emphasis on invasive Candida infections","volume":"43","author":"White","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.blre.2009.11.003_bib34","doi-asserted-by":"crossref","first-page":"376","DOI":"10.2353\/jmoldx.2006.050120","article-title":"A consensus on fungal polymerase chain reaction diagnosis? A United Kingdom-Ireland evaluation of polymerase chain reaction methods for detection of systemic fungal infections","volume":"8","author":"White","year":"2006","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.blre.2009.11.003_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nri1255","article-title":"Immunity to fungal infections","volume":"4","author":"Romani","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.blre.2009.11.003_bib36","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/sj.leu.2404504","article-title":"Diagnosis of invasive aspergillosis by tracking Aspergillus-specific T cells in patients with pulmonary infiltrates","volume":"21","author":"Potenza","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2009.11.003_bib37","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1259\/bjr\/66835905","article-title":"Pulmonary complications following bone marrow transplantation","volume":"76","author":"Wah","year":"2003","journal-title":"Br J Radiol"},{"key":"10.1016\/j.blre.2009.11.003_bib38","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1200\/JCO.2001.19.1.253","article-title":"Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia","volume":"19","author":"Caillot","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2009.11.003_bib39","article-title":"Computer tomography in pulmonary invasive aspergillosis in haematological patients with neutropenia: an useful tool for diagnosis and assessment of outcome in clinical trials","author":"Caillot","year":"2009","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.blre.2009.11.003_bib40","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1086\/521245","article-title":"The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients","volume":"45","author":"Lass-Florl","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib41","doi-asserted-by":"crossref","first-page":"7857","DOI":"10.1200\/JCO.2004.00.8581","article-title":"18F-Fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes","volume":"23","author":"Mahfouz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2009.11.003_bib42","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib43","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/cncr.10610","article-title":"Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta-analysis of randomized-controlled clinical trials","volume":"94","author":"Bow","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2009.11.003_bib44","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood-2002-05-1356","article-title":"Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies","volume":"101","author":"Cornely","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2009.11.003_bib45","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJM199203263261301","article-title":"A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation","volume":"326","author":"Goodman","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2009.11.003_bib46","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/infdis\/171.6.1545","article-title":"Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation\u2014a prospective, randomized, double-blind study","volume":"171","author":"Slavin","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib47","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1200\/JCO.2003.04.052","article-title":"Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3597 patients","volume":"21","author":"Glasmacher","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2009.11.003_bib48","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/jac\/dki440","article-title":"An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia","volume":"57","author":"Glasmacher","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.blre.2009.11.003_bib49","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2009.11.003_bib50","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2009.11.003_bib51","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJMe068266","article-title":"Prophylaxis and aspergillosis\u2014has the principle been proven?","volume":"356","author":"De Pauw","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2009.11.003_bib52","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/sj.bmt.1705614","article-title":"Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy","volume":"39","author":"Trifilio","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2009.11.003_bib53","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1086\/428780","article-title":"Zygomycoses in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases","volume":"191","author":"Kontoyiannis","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib54","doi-asserted-by":"crossref","first-page":"55a","DOI":"10.1182\/blood.V110.11.163.163","article-title":"Results of a randomized, double-blind trial of fluconazole vs. voriconazole for the prevention of invasive fungal infections in 600 allogeneic blood and marrow transplant patients","volume":"110","author":"Wingard","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2009.11.003_bib55","doi-asserted-by":"crossref","unstructured":"Gergis U, Markey K, Greene J, et al. Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD. Bone Marrow Transplant doi:10.1038\/bmt.2009.210.","DOI":"10.1038\/bmt.2009.210"},{"key":"10.1016\/j.blre.2009.11.003_bib56","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ijantimicag.2007.10.001","article-title":"Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study","volume":"31","author":"Cordonnier","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.blre.2009.11.003_bib57","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1086\/586739","article-title":"Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial","volume":"46","author":"Rijnders","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib58","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib59","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1592\/phco.27.12.1644","article-title":"Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients","volume":"27","author":"Chou","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.blre.2009.11.003_bib60","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/jac\/dkn027","article-title":"Risk factors for breakthrough invasive fungal infection during secondary prophylaxis","volume":"61","author":"Cornely","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.blre.2009.11.003_bib61","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ijantimicag.2009.06.025","article-title":"Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry","volume":"34","author":"Vehreschild","year":"2009","journal-title":"Int J Antimicr Ag"},{"issue":"S5","key":"10.1016\/j.blre.2009.11.003_bib62","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejcsup.2007.06.006","article-title":"Primary antifungal prophylaxis in leukaemia patients","author":"Maertens","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.blre.2009.11.003_bib63","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections. http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/infections.pdf."},{"issue":"1","key":"10.1016\/j.blre.2009.11.003_bib64","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.11665","article-title":"Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology","volume":"94","author":"Cornely","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2009.11.003_bib65","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1086\/605665","article-title":"Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO)","volume":"49","author":"Girmenia","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib66","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0002-9343(82)90594-0","article-title":"Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia","volume":"72","author":"Pizzo","year":"1982","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2009.11.003_bib67","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/0959-8049(95)00619-2","article-title":"Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial","volume":"32A","author":"Viscoli","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.blre.2009.11.003_bib68","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1365-2141.1997.2473063.x","article-title":"A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients","volume":"98","author":"Prentice","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2009.11.003_bib69","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0002-9343(98)00326-X","article-title":"A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia","volume":"105","author":"Malik","year":"1998","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2009.11.003_bib70","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1086\/514672","article-title":"Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia","volume":"27","author":"White","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib71","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group","volume":"340","author":"Walsh","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2009.11.003_bib72","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0002-9343(99)00457-X","article-title":"A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer","volume":"108","author":"Winston","year":"2000","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2009.11.003_bib73","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","article-title":"A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph\/ABLC Collaborative Study Group","volume":"31","author":"Wingard","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib74","doi-asserted-by":"crossref","first-page":"412","DOI":"10.7326\/0003-4819-135-6-200109180-00010","article-title":"Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial","volume":"135","author":"Boogaerts","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2009.11.003_bib75","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2009.11.003_bib76","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2009.11.003_bib77","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1086\/496927","article-title":"Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study","volume":"41","author":"Maertens","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib78","article-title":"Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study","author":"Girmenia","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2009.11.003_bib79","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/597395","article-title":"Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial","volume":"48","author":"Cordonnier","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"S5","key":"10.1016\/j.blre.2009.11.003_bib80","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejcsup.2007.06.005","article-title":"Empirical antifungal therapy in neutropenic cancer patients with persistent fever","author":"Marchetti","year":"2007","journal-title":"Eur J cancer"},{"key":"10.1016\/j.blre.2009.11.003_bib81","unstructured":"Prentice AG, Glasmacher A, Hobson RP, et al. Guidelines on the management of invasive fungal infection during therapy for haematological malignancy. http:\/\/www.bcshguidelines.com\/pdf\/IFI_therapy.pdf."},{"key":"10.1016\/j.blre.2009.11.003_bib82","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1056\/NEJM199411173312001","article-title":"A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia","volume":"331","author":"Rex","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2009.11.003_bib83","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0002-9343(96)80072-6","article-title":"Fluconazole versus amphotericin B in the treatment of hematogenus candidiasis: a matched cohort study","volume":"101","author":"Anaissie","year":"1996","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2009.11.003_bib84","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2009.11.003_bib85","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2009.11.003_bib86","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1086\/520980","article-title":"Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis","volume":"45","author":"Pappas","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib87","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(07)60605-9","article-title":"Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial","volume":"369","author":"Kuse","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2009.11.003_bib88","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0140-6736(05)67490-9","article-title":"Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial","volume":"366","author":"Kullberg","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2009.11.003_bib89","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s10096-003-1014-3","article-title":"Voriconazole salvage treatment of invasive candidiasis","volume":"22","author":"Ostrosky-Zeichner","year":"2003","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib90","unstructured":"Arrieta AC, Shea K, Dhar V, et al. Safety of liposomal amphotericin as a once-weekly antifungal prophylactic regimen in very low birth-weight premature infants. P1035, 17th ECCMID 31 March-3 April 2007, Munich."},{"key":"10.1016\/j.blre.2009.11.003_bib91","article-title":"Caspofungin for the treatment of candidaemia in patients with haematological malignancies","author":"Pagano","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.blre.2009.11.003_bib92","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1086\/598933","article-title":"A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis","volume":"48","author":"Betts","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib93","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1002\/cncr.20710","article-title":"Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections","volume":"101","author":"Safdar","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2009.11.003_bib94","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1002\/cncr.21929","article-title":"Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions","volume":"106","author":"Safdar","year":"2006","journal-title":"Cancer"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2009.11.003_bib95","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejcsup.2007.06.007","article-title":"Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients","volume":"5","author":"Herbrecht","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.blre.2009.11.003_bib96","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/596757","article-title":"Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America","volume":"48","author":"Pappas","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib97","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/clinids\/21.5.1145","article-title":"The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses","volume":"21","author":"Oppenheim","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib98","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1086\/516353","article-title":"Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases","volume":"26","author":"Walsh","year":"1998","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.blre.2009.11.003_bib99","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib100","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1086\/515033","article-title":"An EORTC international multicenter randomized trial comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis","volume":"27","author":"Ellis","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib101","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1086\/341401","article-title":"A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients","volume":"35","author":"Bowden","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib102","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0002-9343(94)90023-X","article-title":"NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis","volume":"97","author":"Denning","year":"1994","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2009.11.003_bib103","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1086\/323020","article-title":"Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS","volume":"33","author":"Caillot","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib104","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2009.11.003_bib105","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1086\/510592","article-title":"Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality","volume":"44","author":"Upton","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib106","article-title":"Invasive aspergillosis in patients with acute myeloid leukemia: SEIFEM-2008 registry study","author":"Pagano","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2009.11.003_bib107","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1600-0609.2005.00500.x","article-title":"Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies","volume":"75","author":"Candoni","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2009.11.003_bib108","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkp355","article-title":"Caspofungin as a first-line therapy of invasive aspergillosis in haematological patients. A study of the EORTC Diseases Group","author":"Viscoli","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.blre.2009.11.003_bib109","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1086\/423381","article-title":"Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy","volume":"39","author":"Maertens","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib110","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib111","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/cncr.11115","article-title":"Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin","volume":"97","author":"Aliff","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2009.11.003_bib112","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/cncr.11479","article-title":"Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies","volume":"98","author":"Kontoyiannis","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2009.11.003_bib113","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1002\/cncr.22348","article-title":"Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis","volume":"107","author":"Maertens","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2009.11.003_bib114","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jinf.2006.03.003","article-title":"Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis","volume":"53","author":"Denning","year":"2006","journal-title":"J Infect"},{"key":"10.1016\/j.blre.2009.11.003_bib115","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1086\/423380","article-title":"Combination antifungal therapy for invasive aspergillosis","volume":"39","author":"Marr","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib116","first-page":"496","article-title":"Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin","volume":"22","author":"Raad","year":"2008","journal-title":"Leucemia"},{"key":"10.1016\/j.blre.2009.11.003_bib117","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1086\/513961","article-title":"Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens","volume":"175","author":"Liles","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib118","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00277-008-0622-5","article-title":"Treatment of invasive fungal infections in cancer patients \u2013 recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)","volume":"88","author":"B\u00f6hme","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2009.11.003_bib119","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1445-5994.2008.01725.x","article-title":"Recommendations for the treatment of established fungal infections","volume":"38","author":"Thursky","year":"2008","journal-title":"Intern Med J"},{"key":"10.1016\/j.blre.2009.11.003_bib120","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1046\/j.1365-2141.1997.3983214.x","article-title":"Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA infection","volume":"99","author":"Pagano","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2009.11.003_bib121","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/590004","article-title":"Delaying amphotericin B\u2013based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis","volume":"47","author":"Chamilos","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib122","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/AAC.50.1.126-133.2006","article-title":"Posaconazole as salvage therapy for zygomycosis","volume":"50","author":"Greenberg","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.blre.2009.11.003_bib123","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1086\/500212","article-title":"Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases","volume":"42","author":"van Burik","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib124","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1086\/589857","article-title":"Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis","volume":"47","author":"Reed","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2009.11.003_bib125","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1469-0691.2005.01170.x","article-title":"Hyperbaric oxygen as an adjunctive treatment for zygomycosis","volume":"11","author":"John","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.blre.2009.11.003_bib126","unstructured":"Spellberg B, Bonilla H, Perez M, et al. Safety and outcomes of Deferasirox Iron Chelation therapy for Mucormycosis. 48th ICAAC\/IDSA, 203, 676, 2008, (Abstract M-2175)."},{"key":"10.1016\/j.blre.2009.11.003_bib127","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1128\/AAC.01388-07","article-title":"Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients","volume":"52","author":"Troke","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.blre.2009.11.003_bib128","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cncr.11510","article-title":"Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection","volume":"98","author":"Nucci","year":"2003","journal-title":"Cancer"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X0900068X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X0900068X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T13:48:05Z","timestamp":1590500885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X0900068X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":128,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0268960X0900068X"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2009.11.003","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}